Alzheimer Mechanisms and Therapeutic Strategies

[1]  M. Franceschi,et al.  Decreased CSF concentrations of homovanillic acid and gamma-aminobutyric acid in Alzheimer's disease. Age- or disease-related modifications? , 1982, Archives of Neurology.

[2]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[3]  D. Holtzman,et al.  Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[4]  A. Roses,et al.  Neurodegeneration in the Central Nervous System of apoE-Deficient Mice , 1995, Experimental Neurology.

[5]  J. Morris,et al.  Profound Loss of Layer II Entorhinal Cortex Neurons Occurs in Very Mild Alzheimer’s Disease , 1996, The Journal of Neuroscience.

[6]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[7]  A. Delacourte,et al.  Loss of somatostatin-like immunoreactivity in the frontal cortex of Alzheimer patients carrying the apolipoprotein epsilon 4 allele , 1998, Neuroscience Letters.

[8]  L. Mucke,et al.  Isoform-specific effects of human apolipoprotein E on brain function revealed in ApoE knockout mice: increased susceptibility of females. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  M. Farrer,et al.  Molecular mapping of alzheimer‐type dementia in Down's syndrome , 1998, Annals of neurology.

[10]  B. Dubois,et al.  Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. , 1999, American journal of human genetics.

[11]  S. Paul,et al.  Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[12]  R. Motter,et al.  Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.

[13]  W. Jagust,et al.  The Role of APOE ∊4 in Modulating Effects of Other Risk Factors for Cognitive Decline in Elderly Persons , 1999 .

[14]  A. Fagan,et al.  Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. , 1999, The Journal of clinical investigation.

[15]  Matthias Orth,et al.  Expression of Human Apolipoprotein E3 or E4 in the Brains ofApoe−/− Mice: Isoform-Specific Effects on Neurodegeneration , 1999, The Journal of Neuroscience.

[16]  W. Jagust,et al.  The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. , 1999, JAMA.

[17]  A. Fagan,et al.  Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  V. Haroutunian,et al.  Mitochondrial damage in Alzheimer's disease varies with apolipoprotein E genotype , 2000, Annals of neurology.

[20]  L. Mucke,et al.  beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Makoto Hashimoto,et al.  β-Amyloid peptides enhance α-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  D. Holtzman,et al.  Behavioral Phenotyping of GFAP-ApoE3 and -ApoE4 Transgenic Mice: ApoE4 Mice Show Profound Working Memory Impairments in the Absence of Alzheimer's-like Neuropathology , 2001, Experimental Neurology.

[23]  R. Mahley,et al.  Apolipoprotein E4 Potentiates Amyloid β Peptide-induced Lysosomal Leakage and Apoptosis in Neuronal Cells* , 2002, The Journal of Biological Chemistry.

[24]  L. Mucke,et al.  Modulation of Alzheimer-Like Synaptic and Cholinergic Deficits in Transgenic Mice by Human Apolipoprotein E Depends on Isoform , Aging, and Overexpression of Amyloid β Peptides But Not on Plaque Formation , 2002, The Journal of Neuroscience.

[25]  L. Mucke,et al.  Androgens Protect against Apolipoprotein E4-Induced Cognitive Deficits , 2002, The Journal of Neuroscience.

[26]  Jacob Raber,et al.  Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Mucke,et al.  Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[28]  Robert B Wallace,et al.  Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. , 2003, JAMA.

[29]  J. Morrison,et al.  Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease , 2003, Neurology.

[30]  L. Mucke,et al.  Fyn Kinase Modulates Synaptotoxicity, But Not Aberrant Sprouting, in Human Amyloid Precursor Protein Transgenic Mice , 2004, The Journal of Neuroscience.

[31]  S. Paul,et al.  Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-β peptides , 2004, Nature Medicine.

[32]  R. Mahley,et al.  Astroglial Regulation of Apolipoprotein E Expression in Neuronal Cells , 2004, Journal of Biological Chemistry.

[33]  Tony Wyss-Coray,et al.  Neuron-Specific Apolipoprotein E4 Proteolysis Is Associated with Increased Tau Phosphorylation in Brains of Transgenic Mice , 2004, The Journal of Neuroscience.

[34]  Lars Bäckman,et al.  Apolipoprotein E and cognitive performance: a meta-analysis. , 2004, Psychology and aging.

[35]  Chi Li,et al.  Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Takeshi Iwatsubo,et al.  Inhibition of Heparin-induced Tau Filament Formation by Phenothiazines, Polyphenols, and Porphyrins* , 2005, Journal of Biological Chemistry.

[37]  R. Takahashi,et al.  In vivo evidence of CHIP up‐regulation attenuating tau aggregation , 2005, Journal of neurochemistry.

[38]  E. Masliah,et al.  Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. , 2005, Neuron.

[39]  R. Mahley,et al.  Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[40]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[41]  Makoto Hashimoto,et al.  Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.

[42]  I. Kuntz,et al.  4 enhances amyloid beta peptide production in cultured neuronal cells : ApoE structure as a potential therapeutic target , 2005 .

[43]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[44]  K. Sleegers,et al.  Genetic risk and transcriptional variability of amyloid precursor protein in Alzheimer's disease. , 2006, Brain : a journal of neurology.

[45]  Yadong Huang Molecular and cellular mechanisms of apolipoprotein E4 neurotoxicity and potential therapeutic strategies. , 2006, Current opinion in drug discovery & development.

[46]  D. Campion,et al.  APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy , 2006, Nature Genetics.

[47]  D. Quartermain,et al.  Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's disease , 2006, Proceedings of the National Academy of Sciences.

[48]  R. Mahley,et al.  Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[49]  David Walker,et al.  Profile and Regulation of Apolipoprotein E (ApoE) Expression in the CNS in Mice with Targeting of Green Fluorescent Protein Gene to the ApoE Locus , 2006, The Journal of Neuroscience.

[50]  L. Mucke,et al.  A network dysfunction perspective on neurodegenerative diseases , 2006, Nature.

[51]  L. Mucke,et al.  Reelin Depletion in the Entorhinal Cortex of Human Amyloid Precursor Protein Transgenic Mice and Humans with Alzheimer's Disease , 2007, The Journal of Neuroscience.

[52]  Cam Patterson,et al.  The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins. , 2007, The Journal of clinical investigation.

[53]  Ayodeji A. Asuni,et al.  Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements , 2007, The Journal of Neuroscience.

[54]  H. Soininen,et al.  Somatostatin genetic variants modify the risk for Alzheimer's disease among Finnish patients , 2007, Journal of Neurology.

[55]  Li-Huei Tsai,et al.  Recovery of learning and memory is associated with chromatin remodelling , 2007, Nature.

[56]  R. Vink,et al.  Traumatic brain injury and Alzheimer's disease: a review. , 2007, Progress in brain research.

[57]  H. Arai,et al.  Concurrence of TDP-43, tau and α-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies , 2007, Brain Research.

[58]  S. Maeda,et al.  Molecular chaperone‐mediated tau protein metabolism counteracts the formation of granular tau oligomers in human brain , 2007, Journal of Neuroscience Research.

[59]  J. Silverman,et al.  Cardiovascular risk factors for Alzheimer's disease. , 2007, The American journal of geriatric cardiology.

[60]  J. Trojanowski,et al.  Tau-mediated neurodegeneration in Alzheimer's disease and related disorders , 2007, Nature Reviews Neuroscience.

[61]  Deanna Greenstein,et al.  Cortical morphology in children and adolescents with different apolipoprotein E gene polymorphisms: an observational study , 2007, The Lancet Neurology.

[62]  O. Touloumi,et al.  Activity-Dependent Neuroprotective Protein Snippet NAP Reduces Tau Hyperphosphorylation and Enhances Learning in a Novel Transgenic Mouse Model , 2007, Journal of Pharmacology and Experimental Therapeutics.

[63]  M. Vitek,et al.  COG1410, a novel apolipoprotein E-based peptide, improves functional recovery in a murine model of traumatic brain injury. , 2007, Journal of neurotrauma.

[64]  S. Aalto,et al.  Carbon 11-labeled pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. , 2008, Archives of neurology.

[65]  K. Blennow,et al.  Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial , 2008, The Lancet Neurology.

[66]  L. Mucke,et al.  Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease , 2008, Nature Neuroscience.

[67]  M. Pangalos,et al.  Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels , 2008, The Journal of Neuroscience.

[68]  L. Mucke,et al.  Paths of Convergence: Sirtuins in Aging and Neurodegeneration , 2008, Neuron.

[69]  L. Mucke,et al.  Enkephalin Elevations Contribute to Neuronal and Behavioral Impairments in a Transgenic Mouse Model of Alzheimer's Disease , 2008, The Journal of Neuroscience.

[70]  Katie Hamm,et al.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. , 2008, The Journal of clinical investigation.

[71]  Yadong Huang,et al.  Intron-3 Retention/Splicing Controls Neuronal Expression of Apolipoprotein E in the CNS , 2008, The Journal of Neuroscience.

[72]  Brian Spencer,et al.  The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. , 2008, The Journal of clinical investigation.

[73]  G. McKhann,et al.  Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease , 2008, Nature Medicine.

[74]  T. Gura Hope in Alzheimer's fight emerges from unexpected places , 2008, Nature Network Boston.

[75]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative , 2008 .

[76]  Guojun Bu,et al.  Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy , 2009, Nature Reviews Neuroscience.

[77]  Masanori Nakagawa,et al.  High striatal amyloid beta-peptide deposition across different autosomal Alzheimer disease mutation types. , 2009, Archives of neurology.

[78]  G. Alexander,et al.  Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. , 2009, The New England journal of medicine.

[79]  M. Vitek,et al.  Apolipoprotein E-Mimetics Inhibit Neurodegeneration and Restore Cognitive Functions in a Transgenic Drosophila Model of Alzheimer's Disease , 2009, PloS one.

[80]  E. Masliah,et al.  Reduced IGF-1 Signaling Delays Age-Associated Proteotoxicity in Mice , 2010, Cell.

[81]  K. Weisgraber,et al.  Understanding the Association of Apolipoprotein E4 with Alzheimer Disease: Clues from Its Structure* , 2009, Journal of Biological Chemistry.

[82]  Robert C Green,et al.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. , 2009, JAMA.

[83]  Yong Shen,et al.  Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain , 2009, Proceedings of the National Academy of Sciences.

[84]  J. Becker,et al.  Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[85]  E. Sigurdsson Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. , 2009, Current Alzheimer research.

[86]  E. Weeber,et al.  ApoE4 Decreases Spine Density and Dendritic Complexity in Cortical Neurons In Vivo , 2009, The Journal of Neuroscience.

[87]  Bruce H. Morimoto,et al.  Addressing Alzheimer's disease tangles: from NAP to AL-108. , 2009, Current Alzheimer research.

[88]  D. Berlau,et al.  APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old , 2009, Neurology.

[89]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[90]  J. Trojanowski,et al.  Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies , 2009, Nature Reviews Drug Discovery.

[91]  Hui Zheng,et al.  Amyloid Precursor Protein Regulates Cav1.2 L-type Calcium Channel Levels and Function to Influence GABAergic Short-Term Plasticity , 2009, The Journal of Neuroscience.

[92]  L. Mucke,et al.  Collagen VI protects neurons against Aβ toxicity , 2009, Nature Neuroscience.

[93]  F. Nicoletti,et al.  β-Amyloid Monomers Are Neuroprotective , 2009, The Journal of Neuroscience.

[94]  L. Mucke,et al.  Epilepsy and cognitive impairments in Alzheimer disease. , 2009, Archives of neurology.

[95]  Joachim Herz,et al.  Reelin signaling antagonizes β-amyloid at the synapse , 2009, Proceedings of the National Academy of Sciences.

[96]  P. Matthews,et al.  Distinct patterns of brain activity in young carriers of the APOE e4 allele , 2009, NeuroImage.

[97]  Keith A. Johnson,et al.  Functional Alterations in Memory Networks in Early Alzheimer’s Disease , 2010, NeuroMolecular Medicine.

[98]  L. Schiapparelli,et al.  Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Aβ levels , 2009, Neurobiology of Disease.

[99]  F. Liu,et al.  Human APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice , 2009, The Journal of Neuroscience.

[100]  A. Fagan,et al.  Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. , 2009, Archives of neurology.

[101]  R. Mahley,et al.  GABAergic interneuron dysfunction impairs hippocampal neurogenesis in adult apolipoprotein E4 knockin mice. , 2009, Cell stem cell.

[102]  B. Brew,et al.  Neuropsychological Functioning and Antiretroviral Treatment in HIV/AIDS: A Review , 2009, Neuropsychology Review.

[103]  J. Herz,et al.  ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing ApoE receptor recycling , 2010, Proceedings of the National Academy of Sciences.

[104]  Rie Teraoka,et al.  A Mouse Model of Amyloid β Oligomers: Their Contribution to Synaptic Alteration, Abnormal Tau Phosphorylation, Glial Activation, and Neuronal Loss In Vivo , 2010, The Journal of Neuroscience.

[105]  R. Tanzi,et al.  The Genetics of Alzheimer Disease: Back to the Future , 2010, Neuron.

[106]  Julie A. Harris,et al.  Many Neuronal and Behavioral Impairments in Transgenic Mouse Models of Alzheimer's Disease Are Independent of Caspase Cleavage of the Amyloid Precursor Protein , 2010, The Journal of Neuroscience.

[107]  Karl Herrup,et al.  Reimagining Alzheimer's Disease—An Age-Based Hypothesis , 2010, The Journal of Neuroscience.

[108]  L. Mucke,et al.  Cellular source of apolipoprotein E4 determines neuronal susceptibility to excitotoxic injury in transgenic mice. , 2010, The American journal of pathology.

[109]  Kai Zhang,et al.  Tau Reduction Prevents Aβ-Induced Defects in Axonal Transport , 2010, Science.

[110]  E. Mandelkow,et al.  Aβ Oligomers Cause Localized Ca2+ Elevation, Missorting of Endogenous Tau into Dendrites, Tau Phosphorylation, and Destruction of Microtubules and Spines , 2010, The Journal of Neuroscience.

[111]  W. Klein,et al.  Deleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5 , 2010, Neuron.

[112]  Yadong Huang,et al.  Apolipoprotein E4 Causes Age- and Tau-Dependent Impairment of GABAergic Interneurons, Leading to Learning and Memory Deficits in Mice , 2010, The Journal of Neuroscience.

[113]  Lennart Opitz,et al.  Altered Histone Acetylation Is Associated with Age-Dependent Memory Impairment in Mice , 2010, Science.

[114]  Donald Silberberg,et al.  National Institutes of Health State-of-the-Science Conference Statement: Preventing Alzheimer Disease* and Cognitive Decline , 2010, Annals of Internal Medicine.

[115]  G. Cole,et al.  Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease. , 2010, CNS & neurological disorders drug targets.

[116]  Mathias Jucker,et al.  The benefits and limitations of animal models for translational research in neurodegenerative diseases , 2010, Nature Medicine.

[117]  B. Strooper,et al.  The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.

[118]  I. Bezprozvanny The rise and fall of Dimebon. , 2010, Drug News and Perspectives.

[119]  C. Masters,et al.  Iron-Export Ferroxidase Activity of β-Amyloid Precursor Protein Is Inhibited by Zinc in Alzheimer's Disease , 2010, Cell.

[120]  K. Zahs,et al.  Probing the Biology of Alzheimer's Disease in Mice , 2010, Neuron.

[121]  F. LaFerla,et al.  Alzheimer's disease. , 2010, The New England journal of medicine.

[122]  E. Yaksi,et al.  Acetylation of Tau Inhibits Its Degradation and Contributes to Tauopathy , 2010, Neuron.

[123]  K. J. Lee,et al.  Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines , 2010, Neuroscience.

[124]  J. Trojanowski,et al.  Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy , 2010, The Journal of Neuroscience.

[125]  Michela Gallagher,et al.  Treatment Strategies Targeting Excess Hippocampal Activity Benefit Aged Rats with Cognitive Impairment , 2010, Neuropsychopharmacology.

[126]  Fei Liu,et al.  Tau in Alzheimer disease and related tauopathies. , 2010, Current Alzheimer research.

[127]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[128]  J. Kuret,et al.  Imaging as a strategy for premortem diagnosis and staging of tauopathies. , 2010, Current Alzheimer Research.

[129]  S. Ferreira,et al.  Amyloid-β Peptide Oligomers Disrupt Axonal Transport through an NMDA Receptor-Dependent Mechanism That Is Mediated by Glycogen Synthase Kinase 3β in Primary Cultured Hippocampal Neurons , 2010, The Journal of Neuroscience.

[130]  V. Perry,et al.  Microglia in neurodegenerative disease , 2010, Nature Reviews Neurology.

[131]  Wendy R. Sanhai,et al.  Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives , 2010, Nature Reviews Drug Discovery.

[132]  S. Horvath,et al.  Divergence of human and mouse brain transcriptome highlights Alzheimer disease pathways , 2010, Proceedings of the National Academy of Sciences.

[133]  Brad J Kolls,et al.  A PHASE 2 MULTIPLE ASCENDING DOSE TRIAL OF BAPINEUZUMAB IN MILD TO MODERATE ALZHEIMER DISEASE , 2010, Neurology.

[134]  M. Citron,et al.  Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.

[135]  Jared Stokes,et al.  Temporal lobe functional activity and connectivity in young adult APOE ɛ4 carriers , 2010, Alzheimer's & Dementia.

[136]  K. Zahs,et al.  ‘Too much good news’ – are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? , 2010, Trends in Neurosciences.

[137]  K. Ashe,et al.  Tau Mislocalization to Dendritic Spines Mediates Synaptic Dysfunction Independently of Neurodegeneration , 2010, Neuron.

[138]  Hyoung-Gon Lee,et al.  Antioxidant approaches for the treatment of Alzheimer’s disease , 2010, Expert review of neurotherapeutics.

[139]  L. Mucke,et al.  Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks , 2010, Nature Neuroscience.

[140]  Yadong Huang,et al.  Abeta-independent roles of apolipoprotein E4 in the pathogenesis of Alzheimer's disease. , 2010, Trends in molecular medicine.

[141]  J. Morris,et al.  Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease , 2010, Science.

[142]  H. Steinbusch,et al.  Epigenetic regulation in the pathophysiology of Alzheimer's disease , 2010, Progress in Neurobiology.

[143]  G. Collingridge,et al.  Aβ1–42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β , 2011, Nature Neuroscience.

[144]  R. Huganir,et al.  Arc/Arg3.1 Regulates an Endosomal Pathway Essential for Activity-Dependent β-Amyloid Generation , 2011, Cell.

[145]  S. Rapcsak,et al.  Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes , 2011, Neurology.

[146]  Todd E. Golde,et al.  Anti-Aβ Therapeutics in Alzheimer's Disease: The Need for a Paradigm Shift , 2011, Neuron.

[147]  David M Holtzman,et al.  Human Apoe Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance Nih Public Access , 2022 .

[148]  K. Reymann,et al.  Early neuronal dysfunction by amyloid β oligomers depends on activation of NR2B-containing NMDA receptors , 2011, Neurobiology of Aging.

[149]  N. Schor What the halted phase III γ‐secretase inhibitor trial may (or may not) be telling us , 2011, Annals of Neurology.

[150]  Dietmar R. Thal,et al.  Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years , 2011, Journal of neuropathology and experimental neurology.

[151]  Yong Ji,et al.  Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. , 2011, Journal of Alzheimer's Disease.

[152]  M. Gatz,et al.  Relationship Between Education and Dementia: An Updated Systematic Review , 2011, Alzheimer disease and associated disorders.

[153]  Meaghan Morris,et al.  The Many Faces of Tau , 2011, Neuron.

[154]  Jürgen Götz,et al.  Amyloid-β and tau — a toxic pas de deux in Alzheimer's disease , 2011, Nature Reviews Neuroscience.

[155]  A. Palmeri,et al.  Endogenous amyloid‐β is necessary for hippocampal synaptic plasticity and memory , 2011, Annals of neurology.

[156]  D. Holtzman,et al.  Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-β Amyloidosis , 2011, The Journal of Neuroscience.

[157]  Daniela Galimberti,et al.  Inflammation and oxidative damage in Alzheimer's disease: friend or foe? , 2011, Frontiers in Bioscience.

[158]  J. David Sweatt,et al.  Epigenetic Mechanisms in Cognition , 2011, Neuron.

[159]  M. Mattson,et al.  Aberrant subcellular neuronal calcium regulation in aging and Alzheimer's disease. , 2011, Biochimica et biophysica acta.

[160]  Kewei Chen,et al.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. , 2011, Journal of Alzheimer's disease : JAD.

[161]  K. Yaffe,et al.  The projected effect of risk factor reduction on Alzheimer's disease prevalence , 2011, The Lancet Neurology.

[162]  Julie Harris,et al.  Reversing EphB2 depletion rescues cognitive functions in Alzheimer model , 2011, Nature.

[163]  H. Marie,et al.  Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models? , 2011, Alzheimer's & Dementia.

[164]  R. Mahley,et al.  Small Molecule Structure Correctors Abolish Detrimental Effects of Apolipoprotein E4 in Cultured Neurons* , 2011, The Journal of Biological Chemistry.

[165]  Jee Hoon Roh,et al.  Neuronal activity regulates the regional vulnerability to amyloid-β deposition , 2011, Nature Neuroscience.

[166]  Kimberly Scearce-Levie,et al.  Animal Models of Alzheimer's Disease: Modeling Targets, Not Disease Accelerating Drug Discovery for Alzheimer's Disease: Best Practices for Preclinical Animal Studies , 2022 .

[167]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[168]  D. German,et al.  Identification of Candidate IgG Biomarkers for Alzheimer's Disease via Combinatorial Library Screening , 2011, Cell.

[169]  Clifford R. Jack,et al.  Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup , 2011, Alzheimer's & Dementia.

[170]  Shaomin Li,et al.  Soluble Aβ Oligomers Inhibit Long-Term Potentiation through a Mechanism Involving Excessive Activation of Extrasynaptic NR2B-Containing NMDA Receptors , 2011, The Journal of Neuroscience.

[171]  Yadong Huang,et al.  C-terminal-truncated apolipoprotein (apo) E4 inefficiently clears amyloid-β (Aβ) and acts in concert with Aβ to elicit neuronal and behavioral deficits in mice , 2011, Proceedings of the National Academy of Sciences.

[172]  Chengjie Xiong,et al.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.

[173]  R. Schirmer,et al.  “Lest we forget you — methylene blue …” , 2011, Neurobiology of Aging.

[174]  Phillip B. Jones,et al.  Apolipoprotein E: Isoform Specific Differences in Tertiary Structure and Interaction with Amyloid-β in Human Alzheimer Brain , 2011, PloS one.

[175]  V. Srikanth,et al.  Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease , 2011, Neurobiology of Aging.

[176]  M. Jucker,et al.  Pathogenic protein seeding in alzheimer disease and other neurodegenerative disorders , 2011, Annals of neurology.

[177]  Hélène Marie,et al.  Hippocampal synaptic plasticity in Alzheimer's disease: what have we learned so far from transgenic models? , 2011, Alzheimer's & Dementia.

[178]  Scott A. Peterson,et al.  Structure-dependent Impairment of Intracellular Apolipoprotein E4 Trafficking and Its Detrimental Effects Are Rescued by Small-molecule Structure Correctors* , 2011, The Journal of Biological Chemistry.

[179]  J. Trojanowski,et al.  The acetylation of tau inhibits its function and promotes pathological tau aggregation. , 2011, Nature communications.

[180]  M. Vogt,et al.  APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP , 2011, The EMBO journal.

[181]  J. Kaye,et al.  The aging systemic milieu negatively regulates neurogenesis and cognitive function , 2011, Nature.

[182]  Identification of dihydropyridines that reduce cellular tau levels. , 2011, Chemical Communications.

[183]  H. Braak,et al.  Alzheimer’s pathogenesis: is there neuron-to-neuron propagation? , 2011, Acta Neuropathologica.

[184]  Fred H. Gage,et al.  In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.

[185]  P. Bosco,et al.  APOE and Alzheimer disease: a major gene with semi-dominant inheritance , 2011, Molecular Psychiatry.

[186]  Jurg Ott,et al.  Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study , 2011, Neurobiology of Aging.

[187]  Kelly O'Keefe,et al.  Hippocampal Hyperactivation Associated with Cortical Thinning in Alzheimer's Disease Signature Regions in Non-Demented Elderly Adults , 2011, The Journal of Neuroscience.

[188]  P. Tariot,et al.  A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease , 2011, Neurology.

[189]  M. Ohno,et al.  Therapeutic effects of remediating autophagy failure in a mouse model of Alzheimer disease by enhancing lysosomal proteolysis , 2011, Autophagy.

[190]  Fred H. Gage,et al.  Modelling schizophrenia using human induced pluripotent stem cells , 2011, Nature.

[191]  Ezzie Hutchinson,et al.  Systems neuroscience: The stress of dieting , 2011, Nature Reviews Neuroscience.

[192]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[193]  H. Mori,et al.  Clinical Course of Patients with Familial Early-Onset Alzheimer’s Disease Potentially Lacking Senile Plaques Bearing the E693Δ Mutation in Amyloid Precursor Protein , 2011, Dementia and Geriatric Cognitive Disorders.

[194]  B. Shaby,et al.  Identifying polyglutamine protein species in situ that best predict neurodegeneration , 2011, Nature chemical biology.

[195]  D. Brooks,et al.  Inflammatory risk factors and pathologies associated with Alzheimer's disease. , 2011, Current Alzheimer Research.

[196]  L. Hood,et al.  Systems medicine and integrated care to combat chronic noncommunicable diseases , 2011, Genome Medicine.

[197]  Ralph A. Nixon,et al.  Autophagy failure in Alzheimer's disease—locating the primary defect , 2011, Neurobiology of Disease.

[198]  Robert C Green,et al.  A comprehensive genetic association study of Alzheimer disease in African Americans. , 2011, Archives of neurology.

[199]  A. Gillespie,et al.  Reducing Human Apolipoprotein E Levels Attenuates Age-Dependent Aβ Accumulation in Mutant Human Amyloid Precursor Protein Transgenic Mice , 2012, The Journal of Neuroscience.

[200]  Qian Cai,et al.  Mitochondrial transport in neurons: impact on synaptic homeostasis and neurodegeneration , 2012, Nature Reviews Neuroscience.

[201]  B. Strooper,et al.  The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes , 2012, Nature Neuroscience.

[202]  Kristopher L. Nazor,et al.  Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells , 2012, Nature.

[203]  Jason J. Corneveaux,et al.  A genome-wide scan for common variants affecting the rate of age-related cognitive decline , 2012, Neurobiology of Aging.

[204]  Edward O. Mann,et al.  Inhibitory Interneuron Deficit Links Altered Network Activity and Cognitive Dysfunction in Alzheimer Model , 2012, Cell.

[205]  D. Rubinsztein,et al.  Control of autophagy as a therapy for neurodegenerative disease , 2012, Nature Reviews Neurology.

[206]  A. Salehi,et al.  Neurobiological Elements of Cognitive Dysfunction in Down Syndrome: Exploring the Role of APP , 2012, Biological Psychiatry.

[207]  K. Vossel,et al.  ApoE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease , 2013, Neurocase.

[208]  1 The GloBAl eCoNomiC impACT oF demeNTiA Alzheimer ’ s diseAse internAtionAl World Alzheimer report 2010 the GlobAl economic impAct of dementiA , 2022 .